Category:Breakthrough therapy

This category is for articles primarily about some aspect of breakthrough therapy designation by the United States Food and Drug Administration, an expedited drug development tool, which allows the FDA under Section 902 of the July 9, 2012 Food and Drug Administration Safety and Innovation Act, to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases.